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Abstract
Background: Lipid peroxidation may be a marker of free-radical-mediated injury associated with Alzheimer’s disease (AD).
We aimed to investigate whether changes in lipid peroxidation is associated with cognitive decline in individuals with Down
syndrome over a 4-year period.
Methods: Thirty-two adults with DS participated in a longitudinal study with urinary isoprostane 8,12-iso-iPF2alpha
(iPF2alpha) assays at baseline and four years follow-up. Informants rated their functional ability and memory function and
the adults with DS attempted assessments of language skills and memory. Twenty-six individuals completed assessments of
memory (Modified Memory Object Task, MOMT), adaptive behavior (ABAS), and receptive vocabulary (British Picture
vocabulary, BPVS) at both time-points.
Results: Overall change in iPF2alpha level was negatively correlated with change in the MOMT score (Spearman’s Rho =2
0.576, p = 0.006), i.e., increased lipid peroxidation was correlated with worse memory functioning over time. An increase of
$0.02 ng/mg creatinine iPF2a had good sensitivity (85.7%), positive predictive value (75%,), specificity (85.7%) and negative
predictive value (92.3%) for memory decline.
Conclusion: Change in iPF2alpha over time may have potential as a biomarker for memory decline in Down syndrome and
potentially also help to track progression of MCI to AD in the general population.
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Introduction
Oxidative stress reflects the biological imbalance between
oxidant production and the ability to detoxify the system of
reactive oxygen species (ROS) and repair the damage they cause.
Although low levels of ROS are physiologically important, high
concentrations above the clearance capacity cause mitochondrial
dysfunction, cellular damage, and cell death [1], implicating
oxidative stress as an important mechanism of age-related
pathology [2] such as the cognitive decline associated with
Alzheimer’s Disease (AD) [3].
Down syndrome (DS) has been associated with disturbed
oxidative metabolism, which is assumed to be due to a variety of
mechanisms [4], and most adults with DS will eventually show the
clinical or neuropathological hallmarks of AD [5]. Although this
may be in large part due to the triplication of the APP gene in DS,
increasing evidence suggests that oxidative stress and inflammation
may also play a role in AD pathogenesis associated with the
syndrome [6].
Lipid peroxidation is one of the major outcomes of oxidative
stress following free-radical-mediated injury, leading to the
generation of various end products [7]. Isoprostane 8,12-iso-
iPF2alpha (iPF2alpha) are isomers of the prostagladin F2alpha
produced by ROS attack on polyunsaturated fatty acids. They are
chemically stable, sensitive and specific biomarkers of lipid
peroxidation in vivo [8] and have been shown to be increased in
Alzheimer’s disease, and may mediate the neuronal response to
oxidative stress [9]. Elevated levels of iPF2alpha have been
demonstrated in living adults in DS [10].
Given the DS population’s much increased risk for dementia,
they are an important population in which to study biomarkers of
AD. We aimed to investigate (in an existing research cohort of
adults with DS) whether a peripheral marker of oxidative stress,
specifically a change over time in lipid peroxidation (measured
with urinary iPF2alpha) is associated with cognitive decline in
people with DS, and whether this is related to anti-oxidative
enzyme levels, including Cu/Zn Superoxide dismutase (SOD1).
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Materials and Methods
Study Population, iPF2alpha, Enzyme Assays and
Psychometric Measurements
We used a within-syndrome design to examine the association
between urinary markers of oxidative stress and changes in
cognitive functioning over time in adults with DS. We have
previously established a cohort of 32 individuals with DS who
underwent cognitive testing and donated urine samples for
isoprostane 8,12-iso-iPF2alpha (iPF2alpha) analysis and blood
samples for Cu/Zn superoxide dismutase (SOD1), overall
superoxide dismutase activity (SOD) and glutathione peroxidase
(GPx) analysis. Assays for SOD1, SOD, GPx were measured at
baseline, using methods described elsewhere [11,12].
Urine iPF2alpha levels (corrected for creatinine concentrations)
were measured at both baseline and at follow-up four years later
(mean length of follow up 55.46 months, range 46 to 61 months).
Collection of and processing of urine samples were similar at both
time points. At baseline, urine ipf2alpha levels were measured
using methods described elsewhere [11]. At follow-up, urine
samples were hydrolysed with a 1/10 volume of 1N HCL and
diluted 1:4 with PBS prior to analysis. All reagents for subsequent
8-iso-PGF2alpha analysis were obtained from Cell Biolabs, Inc. 8-
iso-PGF2alpha standards ranging from 200 mg/mL to 0.2 mg/mL
were used to generate a standard curve. Urine samples or
standards were mixed with a 8-iso-PGF2alpha-HRP conjugate for
1 hour at room temperature in a 96-well plate. Wells were washed
5 times with 300 mL wash buffer (1X PBS, 0.05% Tween-20). One
hundred microlitres of HRP substrate was added to each well and
mixed for 30 mins at room temp. The enzyme reaction was
stopped with 100 ml 1 M phosphoric acid the enzyme reaction by
adding 100 mL of Stop Solution to each well. The absorbance was
determined for each well at 450 nM (POLARstar OPTIMA plate-
reader, BMG) and quantified by comparing with the known
predetermined standard curve.
To determine creatinine levels, urine samples were diluted 1:20
with Milli-Q water. Creatinine standards ranging from 20 mg/dl
to 0.078 mg/dl were used to generate a standard curve. Fifty
microliters of standards and samples were added to a 96-well plate
with 200 ml creatinine reaction reagent (Cell Biolabs, Inc.) and
incubated for 30 mins with shaking at room temp. Initial
absorbance values were determined for each well at 490 nM
(POLARstar OPTIMA plate-reader). Fifty microliters creatinine
quencher (Cell Biolabs, Inc.) was added to each well, mixed
thoroughly and incubated for 10 mins at room temp. A final
absorbance value was determined at 490 nM and subtracted from
the initial absorbance giving a corrected absorbance value.
Samples were quantified using by comparing the corrected
absorbance against the known predetermined standard curve.
Details of the psychometric assessments and population
characteristics have also been described elsewhere [11,12]. In
brief, informants (who were in most cases family members)
completed a measure of adaptive behavior (Adaptive Behaviour
Assessment Scale; ABAS [13]) and a dementia screen (the
cognitive scale of the Dementia Scale for people with Learning
Disabilities; DLD [14]). Participants who were able to, completed
a measure of receptive vocabulary (British picture vocabulary
scale; BPVS II [15]), and a modification of an object memory task
(MOMT) based on the Fuld object memory test [16,17]. We
modified the task by reducing the number of objects to 6, and the
number of trials to two.
Ethics Statement and Consent Procedures
The study was approved by the National NHS research ethics
committee and we followed the Mental Capacity Act, UK (2005) if
participants did not have the capacity to consent for themselves, by
gaining agreement from carers. Written informed consent was
obtained for all participants.
Data Analyses
Data was analysed with Statistical Package for the Social
Sciences (SPSS) version 14 [18]. The SOD/GPx activity ration
was calculated from the logarithms of the activities because of the
different orders of magnitude [19]. Correlations between urinary
iPF2alpha levels and baseline factors were examined using
Spearman’s correlations. Correlations between the changes in
psychometric and functional assessments scores (BPVS, ABAS,
MOMT) were examined using Spearman’s correlations. Mann
Whitney U tests were used to compare scores between groups. The
significance level was set at 0.05.
Results
Demographics and Psychometric Tests
Twenty-six out of 32 individuals with DS completed psycho-
metric testing at both time points. Two of the original participants
refused to participate again, and four were lost to follow-up. We
have previously described the demographic features of this cohort
[12]. In summary, the 26 participants had a mean age of
36.6567.05 years, and half of them where males. None were
diagnosed with Alzheimer’s disease at baseline or during the
follow-up period.
Table 1 summarizes the average scores of all psychometric tests
and subtests at follow up and shows the mean change of each score
between baseline and follow-up.
Although total MOMT scores remained relatively stable,
7(33.3%) participants showed decline on MOMT scores between
T1 and T2.
iPF2alpha Measurements and Enzyme Assays
Data on urinary iPF2a were available for 24 patients at baseline
and follow-up. For these 24 patients, at baseline, the range of
iPF2alpha was 0.16 to 3.18 ng/mg creatinine (mean 1.3960.79)
and at follow-up 0.52 to 5.27 ng/mg creatinine (mean 1.3861.23).
The change between iPF2a levels at follow up and at baseline
ranged from 22.60 to +4.30 ng/mg creatinine (mean
0.00361.56). Table 2 presents individual values for all patients,
at both baseline and follow-up.
The mean change in the iPF2a levels did not correlate with age
(Spearman’s rho= 0.074, p= 0.731), nor did it differ between
males and females (Student’s t-test, t value =20.715, p = 0.482),
patients with thyroid disorder and those without (Mann-Whitney
U, Z value =20.400, p= 0.689), mild ID or moderate to severe
ID (Mann-Whitney U, Z value =20.306, p = 0.760), and white
UK or those of other ethnicity (Mann-Whitney U, Z value =2
1.333, p = 0.182). However, those receiving vitamins and supple-
ments at baseline presented with increased urinary levels of iPF2a
(mean change +0.882 ng/mg) compared to those who were not
(mean change 20.404 ng/mg); t value =21.975; p = 0.02.
Relationship between Oxidative Enzymes and Urinary
iPF2alpha
Table 3 summarizes the correlations between baseline enzyme
assays, urine iPF2alpha at follow-up, and change in iPF2alpha
over time. Correlations between baseline enzyme assays and
Urinary iPF2alpha and Memory Decline in Down Syndrome
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baseline urine iPF2alpha have been presented elsewhere [11].
Enzyme assays at baseline were not correlated significantly with
urinary iPF2alpha at follow up, or the change in urinary
iPF2alpha levels over the 4-year period. However, there was a
trend towards a negative relationship between overall SOD
function at baseline and change in iPF2alpha over time. A trend
towards a similar relationship was also noted for GPx (i.e. better
SOD function and higher GPx levels may be related to less change
in iPF2alpha over 4 years).
Relationship between Urinary iPF2alpha and Cognitive
Ability Changes
Table 4 lists the correlations between levels of iPF2alpha and
performance over 4 years on tests of functional ability, memory or
language ability. Correlations between baseline psychometric
measures and baseline urine iPF2alpha have been presented
elsewhere [11]. There were no statistically significant correlations
between levels of ipF2alpha level at follow up or its change over 4
years and ABAS total score, or with ABAS functional academic
Table 1. Mean scores and 95% confidence intervals of psychometric tests at baseline, follow up and change between time points.
Baseline (t1) Follow-up (t2) Mean change i.e. t2–t1
ABAS
Functional academics 30.4 (21.6–39.2) 25.1 (17.9–32.3) –5.3 (29.3–21.4)
Total score 366.8 (312.7–421.0) 317.9 (263.9–371.8) –49.0 (271.1–226.9)
BPVS
Raw score 61.6 (53.1–70.2) 55.7 (46.3–65.1) –6.0 (29.1–22.8)
Age equivalent, in months 73.1 (62.3–83.9) 66.4 (54.4–78.4) n/a
MOMT
Delayed recall 4.7 (4.3–5.2) 4.8 (4.4–5.3) 0.1 (20.4–0.6)
Total score 12.6 (11.9–13.4) 13.0 (12.3–13.7) 0.4 (20.4–1.2)
doi:10.1371/journal.pone.0097709.t001
Table 2. Individual values of urinary ipf2alpha for both baseline and follow up.
Patient Gender
Age at baseline,
in years
Ipf2a at baseline,
in ng/mg creatinine
Ipf2a at follow up,
in ng/mg creatinine
#1 Female 40 .22 .89
#2 Female 22 1.19 .87
#3 Female 33 1.75 .87
#4 Male 45 1.04 4.42
#5 Female 27 1.22 .57
#6 Female 30 .86 1.16
#7 Male 26 3.18 .58
#8 Male 31 1.45 1.16
#9 Female 36 1.31 .62
#10 Male 35 2.12 1.79
#11 Female 30 1.05 1.04
#12 Female 25 1.24 3.49
#13 Male 32 .97 5.27
#14 Female 22 1.75 .67
#15 Male 36 1.12 .90
#16 Male 39 2.86 1.41
#17 Female 35 3.16 1.06
#18 Female 40 1.33 .68
#19 Male 35 .72 .97
#20 Male 27 1.51 .52
#21 Female 24 .16 1.44
#22 Female 30 1.55 .62
#23 Male 18 .60 1.27
#24 Male 41 .93 .95
doi:10.1371/journal.pone.0097709.t002
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score. However, overall change in iPF2alpha level was negatively
correlated with change in the MOMT total score (Spearman’s
Rho=20.516, p= 0.017) and MOMT delayed recall score
(Spearman’s Rho=20.576, p = 0.006). Increases in lipid perox-
idation were correlated with worse memory functioning over time.
An increase equal to or more than 0.02 ng/mg creatinine in
iPF2alpha identified 6 out of 7 participants who showed declines
on memory tasks (sensitivity = 85.7%; positive predictive val-
ue = 75%) and included only 2 of 14 participants who did not
show memory decline (specificity = 85.7%; negative predictive
value = 92.3%).
Discussion
Findings
We have previously shown that serum levels of SOD predicts
memory decline over time [12]. In the present study, we have
explored the relationship between cognitive change over time in
adults with DS and urinary markers of oxidative stress, which
suggests that there is a correlation between increased oxidative
stress measured with lipid peroxidation and memory decline in
adults with DS over time. Our results suggest that an increase in
iPF2alpha, but not absolute iPF2alpha titers, is an early marker of
progression to AD in DS, and that increased lipid peroxidation
can predict decline on memory tests in this population with good
sensitivity and specificity.
Table 3. Correlations between anti-oxidant enzymes in blood and urinary iPF2alpha.
iPF2alpha at follow-up (t2) Change in iPF2alpha (t2–t1)
SOD function Spearman’s Rho 20.406 20.444
p 0.076 0.065
N 20 18
SOD enzyme units Spearman’s Rho 20.128 20.065
p 0.612 0.811
N 18 16
GPx Spearman’s Rho 20.400 20.420
p 0.081 0.082
N 20 18
SOD function/GPx Spearman’s Rho 0.186 0.207
p 0.431 0.409
N 20 18
doi:10.1371/journal.pone.0097709.t003
Table 4. Correlations between changes in psychometric measures (scores at follow up minus score at baseline), and urinary
iPF2alpha titers.
iPF2alpha at follow-up Change in iPF2alpha
Change in ABAS total score Spearman’s Rho 0.215 0.188
p 0.292 0.379
N 26 24
Change in ABAS functional academic score Spearman’s Rho 0.118 20.241
p 0.566 0.256
N 26 24
Change in BPVS raw score Spearman’s Rho 20.204 20.178
p 0.363 0.440
N 22 21
Change in MOMT total score Spearman’s Rho 20.195 20.516
p 0.397 0.017*
N 21 21
Change in MOMT delayed recall score Spearman’s Rho 20.258 20.576
p 0.259 0.006**
N 21 21
*means p,0.05 when **means p,0.01.
doi:10.1371/journal.pone.0097709.t004
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Implications
Our results suggest that increases in urinary iPF2alpha over
time are associated with the memory decline that is typical of AD
in adult participants with DS, an ultra-high risk group for
developing dementia.
In keeping with our results, a general population study of AD
found that an increase in isoprostane levels in CSF (rather than
absolute values) was associated with progression of mild cognitive
impairment (MCI) to AD and with cognitive decline over time,
and that this marker was more predictive of progression than other
AD biomarkers [20]. Taken together, our study (in adults with DS)
and the CSF study (with participants without DS) suggest that
markers of oxidative stress have considerable potential as a
biomarkers of the cognitive decline suggestive of MCI, and of
progression of AD symptoms. Although absolute values of
isoprostanes may not have much value in screening for AD,
increased levels over time have considerable potential to track
progression of disease. Given that urine samples are easier to
obtain than CSF, our results have important practical implica-
tions.
It has been suggested that oxidative stress is an important
consequence of the specific biology of DS, and is likely to play a
role in some of the co-morbidities associated with DS, including
the tendency to develop AD [4]. Oxidative damage may lead to
enhanced amyloid beta peptide (Ab) production [21–24] and in a
recent study, Cenini et al. showed that soluble and insoluble Ab
and oligomers increase as a function of age in DS frontal cortex,
and that Ab40 correlated with protein carbonyls (an oxidative
stress marker), which suggests that oxidative damage may
contribute to the onset and progression of AD pathogenesis in
DS [25]. The exact mechanism is still unknown, but Yang et al.
showed that ROS enhanced amyloid toxicity in the neurons of
APP/PS1 mice [26], an AD mouse model with excessive amyloid
production which is also found in DS, while Di Domenico et al
demonstrated that oxidation of proteins is an early event in DS
and might contribute to neurodegenerative phenomena [27].
Peripheral biomarkers of oxidative stress in Down syndrome
include SOD [12,26,28], GPx [6,29], uric acid [29], plasma
melatonin, urinary kynurenine [30], gelsolin [31], nitric oxide
[32,33] and neopterin [34]. However, oxidative stress or lipid
peroxidation may not necessarily be increased in DS. Tolun et al.
compared the levels of urinary allantoin and F2-isoprostanes
between individuals with DS and controls without finding any
significant difference [35]. Moreover, Campos et al assessed a set
of urinary oxidative stress biomarkers in children with DS
including 8-hydroxy-29-deoxyguanosine (8-OHdG), isoprostane
15-F2t-IsoP, thiobarbituric acid-reacting substances (TBARS),
advanced glycation end products (AGEs), dityrosine (diTyr),
hydrogen peroxide (H2O2) and nitrite/nitrate (NOx) and found
that only levels of diTyr were increased in DS, although no
differences were obtained when hypothyroid DS children were
excluded [36]. In another study, Campos et al, aimed to assess the
same set of oxidative and nitrosative stress biomarkers in urine
samples of adolescents and adults with DS, with and without
hypothyroidism and concluded that some biomarkers such as 8-
OHdG, 15-F2t-IsoP and TBARS may be prone to age effects,
renal function, and thyroid function [37]. In contrast, we did not
find any correlation between changes in iPF2alpha over time and
age, nor an effect for thyroid disorder.
It has been demonstrated that premature aging in kidneys of DS
patients could lead to an impaired renal function [38]. For this
reason, not only the oxidative status but also the alteration of the
glomerular filtration rate could affect nitrite and nitrate levels in
DS patients. Therefore, Ripoll et al conducted a comparative
study assessing nitrosative stress biomarkers in plasma samples
from adult DS patients [39], concluding that the increased levels of
nitrates found in urine samples of adult DS patients [37] are also
found in plasma samples, which confirms the use of nitrogen
reactive species as stress biomarkers in adult DS patients.
Increases in the anti-oxidant systems in DS (such as SOD) help
to protect against increased oxidative stress [40]. Our results are in
keeping with these studies – we have previously demonstrated a
positive relationship between SOD1 and better memory function,
while the present results indicate that when the protective
mechanisms fail over time and lipid peroxidation increases, it is
associated with decline in memory function.
Lastly, increased lipid peroxidation has been shown to precede
amyloid plaque formation in some studies of animal models [24]
and lipid peroxidation may trigger neurodegeneration [22];
reduction of oxidative stress could therefore be a potential
treatment target in the DS population.
Strengths and Limitations
We undertook a prospective cohort study of adults with DS, in
which we managed to follow up 80% of the initial study group
over an unusually long period (4 years). We have included
participants with the full range of cognitive abilities associated with
DS, and our sample is therefore representative of the wide
variation in intellectual phenotype. However, our sample size was
relatively small, and our results need to be confirmed with a
replication study.
We were not able to control for all possible confounders as, for
example, cognitive performance may be influenced by educational
exposure, though in the UK all adults with DS have equal access
to education. Moreover, it is likely that dietary intake of food with
antioxidant properties varied across participants and we did not
collect sufficient detail on compliance with vitamin supplementa-
tion during the follow-up period to include this in our analysis.
The technique of measurement of ipf2alpha at follow up was
different at follow-up compared to baseline (where gas chroma-
tography and mass spectrometry i.e. GC/MS was used). When
immunoassays are performed under appropriate conditions, values
obtained for isoprostanes obtained by immunoassay often corre-
late well (r2.0.8) with values obtained by the standard GC/MS
method [41].
Among the followed-up population, there were no patients with
translocation, and there was only one patient with mosaicism.
Therefore, we were not able to study the relationship between
iPF2alpha levels and these categories in more detail. The study
was powered to detect correlations of moderate strength and it is
therefore possible to have missed more subtle relationships. For
example, a significant relationship between SOD and GPx and
changes in lipid peroxidation may become apparent in larger
studies.
Conclusion
For the first time, it is suggested that change in urinary
iPF2alpha over time is associated with memory decline in people
with DS, suggesting that sequential measurements of urinary
iPF2alpha may have potential as biomarker for cognitive decline
and progression to AD in this population. This preliminary finding
adds to similar studies in the general population, which showed
increased isoprostanes in the CSF of people with MCI who have
progressed to full-blown AD. Furthermore, the association
between an increase in lipid peroxidation and cognitive decline
in relatively young adults with DS suggests that reduction of
oxidative stress and consequent lipid peroxidation may be a
Urinary iPF2alpha and Memory Decline in Down Syndrome
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potential treatment strategy to reduce the high risk for AD in this
population.
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